Show simple item record

dc.contributor.authorKilpelainen, TP
dc.contributor.authorTammela, TLJ
dc.contributor.authorRoobol, M
dc.contributor.authorHugosson, J
dc.contributor.authorCiatto, S
dc.contributor.authorNelen, V
dc.contributor.authorMoss, S
dc.contributor.authorMaattanen, L
dc.contributor.authorAuvinen, A
dc.date.accessioned2018-08-13T10:54:45Z
dc.date.issued2011-12
dc.identifier18
dc.identifier.citationEUROPEAN JOURNAL OF CANCER, 2011, 47 pp. 2698 - 2705
dc.identifier.issn0959-8049
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/2318
dc.identifier.doi10.1016/j.ejca.2011.06.055
dc.description.abstractBackground: Screening for prostate cancer (PC) with prostate-specific antigen (PSA) has been shown to decrease mortality, but has adverse effects, such as false-positive (FP) screening results. We describe the frequency of FP results and assess their relation to subsequent screening attendance, test results and prostate cancer risk in a large randomized trial. Materials and methods: We included data from five centres of the European Randomized Study of Screening for Prostate Cancer, altogether over 61,000 screened men. Men were screened with PSA test at a 2-7 year interval depending on the centre; PSA cut-off was 3.0-4.0 ng/ml. A positive screen with no histologically confirmed PC in biopsy within 1 year was defined as an FP result. Results: Of the 61,604 men who were screened at least once, 17.8% had one or more FP result(s). Almost 20% of men who participated at all screening rounds had one or more FP result(s). More than half of the men with an FP result had another FP if screened again. Men with FP results had a fourfold risk of PC at subsequent screen (depending on the round, 10.0% versus 2.6-2.7% of men with negative screen, risk ratio 3.8-3.9). The PCs following an FP result were in 92.8% of cases localised and low-grade versus 90.4% following a screen-negative result. Conclusions: Our results show that FP results are common adverse effects in PC screening, as they affect at least one in six screened men. False-positive men are more prone to be diagnosed with PC but are also likely to have consistently high PSA levels. (C) 2011 Elsevier Ltd. All rights reserved.
dc.format.extent2698 - 2705
dc.languageeng
dc.language.isoeng
dc.publisherELSEVIER SCI LTD
dc.titleFalse-positive screening results in the European randomized study of screening for prostate cancer
dc.typeJournal Article
rioxxterms.versionofrecord10.1016/j.ejca.2011.06.055
rioxxterms.licenseref.startdate2011-12
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfEUROPEAN JOURNAL OF CANCER
pubs.notesaffiliation: Kilpelainen, TP (Reprint Author), Univ Tampere, Tampere Sch Publ Hlth, FIN-33014 Tampere, Finland. Kilpelainen, Thomas P.; Auvinen, Anssi, Univ Tampere, Tampere Sch Publ Hlth, FIN-33014 Tampere, Finland. Kilpelainen, Thomas P.; Tammela, Teuvo L. J., Tampere Univ Hosp, Dept Urol, Tampere, Finland. Roobol, Monique, Erasmus, Dept Urol, MC, Rotterdam, Netherlands. Hugosson, Jonas, Sahlgrens Univ Hosp, Dept Urol, Gothenburg, Sweden. Ciatto, Stefano, ISPO, Dept Diagnost Med Imaging, Florence, Italy. Nelen, Vera, Provinciaal Inst Hyg, Antwerp, Belgium. Moss, Sue, Inst Canc Res, Canc Screening Evaluat Unit, Surrey, England. Maattanen, Liisa, Finnish Canc Registry, Helsinki, Finland. keywords: Mass screening; Prostatic neoplasms; PSA; Randomized controlled trials; Sensitivity and specificity keywords-plus: LEAD-TIME; ANTIGEN; TRIAL; PSA; BIOPSY; MEN; OVERDIAGNOSIS; NETHERLANDS; ROTTERDAM; FEATURES research-areas: Oncology web-of-science-categories: Oncology author-email: [email protected] orcid-numbers: Kilpelainen, Tuomas P./0000-0002-7697-0148 Auvinen, Anssi/0000-0003-1125-4818 funding-acknowledgement: European Randomised Study of Screening for Prostate Cancer (ERSPC); European Union; Beckman-Coulter-Hybritech Inc.; numerous local grants funding-text: The international coordination of the European Randomised Study of Screening for Prostate Cancer (ERSPC) has been supported since the study’s initiation in 1991 by grants from Europe Against Cancer and the fifth and sixth framework programme of the European Union, by many grants from agencies in the individual participating countries and by unconditional grants from Beckman-Coulter-Hybritech Inc. The studies in each national centre were funded by numerous local grants. number-of-cited-references: 31 times-cited: 13 usage-count-last-180-days: 0 usage-count-since-2013: 4 journal-iso: Eur. J. Cancer doc-delivery-number: 867LW unique-id: ISI:000298456900005 da: 2018-08-13
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams/Cancer Screening Evaluation Unit (DoH)
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams/Cancer Screening Evaluation Unit (DoH)
pubs.volume47
pubs.embargo.termsNot known
icr.researchteamCancer Screening Evaluation Unit (DoH)en_US
dc.contributor.icrauthorMoss, Susan Maryen


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following collection(s)

Show simple item record